Yervoy Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Yervoy is a prescription medication containing ipilimumab, a monoclonal antibody used to treat certain cancers by enhancing the body's immune system to fight cancer cells. It works by blocking the CTLA-4 (cytotoxic T-lymphocyte antigen 4) receptor on T-cells, which normally downregulates the immune response.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of yervoy are the 40 ml and 10 ml doses. The Yervoy 40 mg dose refers to a specific concentration of ipilimumab, used in immunotherapy to activate the immune system by inhibiting CTLA-4. This enhances the body's ability to target and destroy cancer cells, especially in conditions like metastatic melanoma and other cancers as per the prescribed treatment regimen. Yervoy is indicated for melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and colorectal cancer (CRC). It is distributed through various channels such as hospitals, oncology clinics, retail pharmacies, and online pharmacies, and is used by various end users including adults and the geriatric population.

The yervoy market research report is one of a series of new reports from The Business Research Company that provides yervoy market statistics, including yervoy industry global market size, regional shares, competitors with a yervoy market share, detailed yervoy market segments, market trends, and opportunities, and any further data you may need to thrive in the yervoy industry. This yervoy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The yervoy market size is expected to see rapid growth in the next few years. It will grow to $9,000 million in 2029 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to rising consumer demand in emerging markets, expanding applications across industries, advancements in clinical research, increasing investment in biologics, and global market expansion. Major trends in the forecast period include expansion of combination immunotherapies, broadening of indications for new cancers, advancements in biologic drug delivery systems, increasing role of artificial intelligence (AI) in oncology, and patient-centric drug development.

The growing incidence of melanoma is expected to drive the expansion of the yervoy market. Melanoma is a form of skin cancer that originates in melanocytes, the cells responsible for producing melanin, the pigment that gives skin its color. The rise in melanoma cases can be attributed to factors like increased sun exposure, lifestyle changes, and higher UV radiation levels due to ozone depletion. Additionally, better awareness and diagnostic techniques have led to more cases being identified. Yervoy, which targets the CTLA-4 protein to enhance the immune system's ability to recognize and destroy cancer cells, has shown significant benefits for melanoma patients, improving survival rates and providing long-lasting responses even in the later stages of the disease. According to the American Cancer Society, about 100,640 new melanoma cases are expected in the United States in 2024, with 59,170 in men and 41,470 in women. The society also estimates that 8,290 people will die from melanoma in 2024, with 5,430 men and 2,860 women affected. As a result, the rising number of melanoma cases is driving growth in the yervoy market.

A key trend in the yervoy market is the development of innovative combination therapies, such as pairing Opdivo (nivolumab) with Yervoy (ipilimumab) to improve treatment outcomes and extend their application to more cancer types. This combination works synergistically to enhance the immune response by targeting different immune checkpoint pathways, which improves effectiveness in treating cancers like melanoma and renal cell carcinoma. For example, in June 2024, Bristol Myers Squibb, a US-based pharmaceutical company, announced promising results from the CheckMate-9DW trial. The trial tested the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The results showed that this dual immunotherapy significantly improved overall survival compared to the standard treatments, lenvatinib or sorafenib. The combination demonstrated a statistically significant survival benefit for advanced HCC patients compared to those treated with either lenvatinib or sorafenib.

In September 2024, Ono Pharmaceutical, a Japanese pharmaceutical company, formed a partnership with Bristol-Myers Squibb KK (BMS KK) to expand the use of Opdivo and Yervoy for treating unresectable advanced or recurrent microsatellite instability-high (MSI-H) colorectal cancer. This collaboration aims to strengthen Ono's portfolio of immuno-oncology therapies and address the unmet medical needs in cancer treatment. Bristol-Myers Squibb is the company behind Yervoy.

Major players operating in the yervoy market are Bristol-Myers Squibb, Merck & Co., and Ono Pharmaceutical.

North America was the largest region in the yervoy market in 2024. The regions covered in yervoy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the yervoy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The yervoy market consists of sales of ipilimumab and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Yervoy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on yervoy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for yervoy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The yervoy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 40 ml; 10 ml
• 2) By Clinical Indication: Melanoma; Non-Small Cell Lung Cancer (NSCLC); Renal Cell Carcinoma (RCC); Colorectal Cancer (CRC)
• 3) By Distribution Channel: Hospitals; Oncology Clinics; Retail Pharmacies; Online Pharmacies
• 4) By End User: Adult; Geriatric
• Companies Mentioned: Bristol-Myers Squibb; Merck & Co.; Ono Pharmaceutical
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.